Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy
D'Souza, R., Main, J., Crossey, M., Rosenberg, W., Murray-Lyon, I.M., Hayward, C. and Foster, G.R. (2005) Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy. Alimentary Pharmacology and Therapeutics, 21, (1), 43-47. (doi:10.1111/j.1365-2036.2004.02295.x).
Full text not available from this repository.
Background: Current therapy for chronic hepatitis C infection involves a course of pegylated interferon and ribavirin. Patients who do not show a virological response after 12 weeks of therapy have a low probability of sustained virological response and it is therefore recommended that such patients stop treatment.
Aim: To assess patients' views of early treatment cessation.
Methods: We conducted a open-labelled study in three UK centres, in which patients with biopsy-proven chronic hepatitis C requiring therapy were offered the choice of a full course of therapy with 40 kDa pegylated interferon-α 2a plus ribavirin (24 or 48 weeks depending on viral genotype) or early cessation if therapy had failed after 12 weeks.
Results: Ninety-five participants were enrolled and the majority (69%) did not wish to discontinue therapy even if it had low probability of success. In this unselected UK population, very few patients (4%) did not achieve an early virological response with the 40-kDa pegylated interferon-α 2a plus ribavirin and two of the four early virological non-responders decided to continue therapy.
Conclusion: Early discontinuation of 'ineffective' anti-viral therapy may prove less popular with patients than with health care providers, and further patient-directed education regarding the cost-effectiveness of therapy will be needed if early discontinuation of unsuccessful therapy is to be accepted by patients.
|Subjects:||Q Science > QR Microbiology > QR355 Virology
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
|Date Deposited:||25 Apr 2006|
|Last Modified:||02 Mar 2012 13:27|
|Contributors:||D'Souza, R. (Author)
Main, J. (Author)
Crossey, M. (Author)
Rosenberg, W. (Author)
Murray-Lyon, I.M. (Author)
Hayward, C. (Author)
Foster, G.R. (Author)
|Contact Email Address:||email@example.com|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)